Johnson & Johnson Pre-Paid Expenses 2010-2024 | JNJ
Johnson & Johnson pre-paid expenses from 2010 to 2024. Pre-paid expenses can be defined as a current asset created by prepayment of costs and expenses for which the benefits will occur at a future date.
- Johnson & Johnson pre-paid expenses for the quarter ending September 30, 2024 were $4.175B, a 0.5% decline year-over-year.
- Johnson & Johnson pre-paid expenses for 2023 were $4.514B, a 56.95% increase from 2022.
- Johnson & Johnson pre-paid expenses for 2022 were $2.876B, a 22.29% decline from 2021.
- Johnson & Johnson pre-paid expenses for 2021 were $3.701B, a 18.17% increase from 2020.
Johnson & Johnson Annual Pre-Paid Expenses
(Millions of US $) |
| 2023 |
$4,514 |
| 2022 |
$2,876 |
| 2021 |
$3,701 |
| 2020 |
$3,132 |
| 2019 |
$2,392 |
| 2018 |
$2,699 |
| 2017 |
$2,537 |
| 2016 |
$3,282 |
| 2015 |
$3,047 |
| 2014 |
$3,486 |
| 2013 |
$4,003 |
| 2012 |
$3,084 |
| 2011 |
$2,633 |
| 2010 |
$2,273 |
| 2009 |
$2,497 |
Johnson & Johnson Quarterly Pre-Paid Expenses
(Millions of US $) |
| 2024-09-30 |
$4,175 |
| 2024-06-30 |
$4,379 |
| 2024-03-31 |
$4,455 |
| 2023-12-31 |
$4,514 |
| 2023-09-30 |
$4,196 |
| 2023-06-30 |
$2,397 |
| 2023-03-31 |
$2,921 |
| 2022-12-31 |
$2,876 |
| 2022-09-30 |
$3,592 |
| 2022-06-30 |
$3,703 |
| 2022-03-31 |
$3,452 |
| 2021-12-31 |
$3,701 |
| 2021-09-30 |
$3,590 |
| 2021-06-30 |
$3,492 |
| 2021-03-31 |
$3,024 |
| 2020-12-31 |
$3,132 |
| 2020-09-30 |
$2,528 |
| 2020-06-30 |
$2,588 |
| 2020-03-31 |
$2,358 |
| 2019-12-31 |
$2,392 |
| 2019-09-30 |
$2,220 |
| 2019-06-30 |
$2,411 |
| 2019-03-31 |
$2,599 |
| 2018-12-31 |
$2,699 |
| 2018-09-30 |
$2,896 |
| 2018-06-30 |
$2,569 |
| 2018-03-31 |
$2,641 |
| 2017-12-31 |
$2,537 |
| 2017-09-30 |
$2,922 |
| 2017-06-30 |
$2,954 |
| 2017-03-31 |
$2,826 |
| 2016-12-31 |
$3,282 |
| 2016-09-30 |
$2,600 |
| 2016-06-30 |
$3,122 |
| 2016-03-31 |
$3,307 |
| 2015-12-31 |
$3,047 |
| 2015-09-30 |
$3,010 |
| 2015-06-30 |
$3,058 |
| 2015-03-31 |
$3,731 |
| 2014-12-31 |
$3,486 |
| 2014-09-30 |
$3,107 |
| 2014-06-30 |
$3,982 |
| 2014-03-31 |
$3,932 |
| 2013-12-31 |
$4,003 |
| 2013-09-30 |
$3,312 |
| 2013-06-30 |
$3,425 |
| 2013-03-31 |
$3,260 |
| 2012-12-31 |
$3,084 |
| 2012-09-30 |
$2,789 |
| 2012-06-30 |
$2,894 |
| 2012-03-31 |
$2,683 |
| 2011-12-31 |
$2,633 |
| 2011-09-30 |
$3,056 |
| 2011-06-30 |
$3,290 |
| 2011-03-31 |
$3,021 |
| 2010-12-31 |
$2,273 |
| 2010-09-30 |
$2,474 |
| 2010-06-30 |
$3,172 |
| 2010-03-31 |
$3,293 |
| 2009-12-31 |
$2,497 |
| 2009-09-30 |
$2,768 |
| 2009-06-30 |
$2,719 |
| 2009-03-31 |
$3,374 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$368.366B |
$85.159B |
|
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
|
